[go: up one dir, main page]

HN2005000005A - Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779 - Google Patents

Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779

Info

Publication number
HN2005000005A
HN2005000005A HN2005000005A HN2005000005A HN2005000005A HN 2005000005 A HN2005000005 A HN 2005000005A HN 2005000005 A HN2005000005 A HN 2005000005A HN 2005000005 A HN2005000005 A HN 2005000005A HN 2005000005 A HN2005000005 A HN 2005000005A
Authority
HN
Honduras
Prior art keywords
cci
direct compression
pharmaceutical composition
oral administration
composition suitable
Prior art date
Application number
HN2005000005A
Other languages
English (en)
Inventor
Ashraf Mahummad
J Benjamin Eric
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HN2005000005A publication Critical patent/HN2005000005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION CCI-779 MICRONIZADO, ESTE 42-ESTER DE RAPAMICINA CON ACIDO - 3-HIDROXI-2- (HIDROXIMETIL)-2-METILPROPIONICO APTAO PARA LA COMPRESION DIRECTA OFRECE UN METODO CONVENIENTE Y EFICAZ PARA ADMINISTRAR NIVELES TERAPEUTICOS CCI-779 A UN PACIENTE.
HN2005000005A 2004-01-08 2005-01-06 Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779 HN2005000005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
HN2005000005A true HN2005000005A (es) 2009-04-17

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2005000005A HN2005000005A (es) 2004-01-08 2005-01-06 Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779

Country Status (30)

Country Link
US (1) US20050152983A1 (es)
EP (1) EP1701698B1 (es)
JP (1) JP2007517879A (es)
KR (1) KR20060130162A (es)
CN (1) CN1921861A (es)
AR (1) AR047180A1 (es)
AT (1) ATE383859T1 (es)
AU (1) AU2004314213A1 (es)
BR (1) BRPI0418373A (es)
CA (1) CA2552595A1 (es)
CR (1) CR8491A (es)
CY (1) CY1107373T1 (es)
DE (1) DE602004011398T2 (es)
DK (1) DK1701698T3 (es)
EC (1) ECSP066757A (es)
ES (1) ES2298861T3 (es)
GT (1) GT200500003A (es)
HN (1) HN2005000005A (es)
IL (1) IL176519A0 (es)
MX (1) MXPA06007829A (es)
NO (1) NO20062930L (es)
PA (1) PA8621201A1 (es)
PE (1) PE20050683A1 (es)
PL (1) PL1701698T3 (es)
PT (1) PT1701698E (es)
RU (1) RU2006122517A (es)
TW (1) TW200526213A (es)
UA (1) UA84903C2 (es)
WO (1) WO2005070393A2 (es)
ZA (1) ZA200605631B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
BRPI0509852A (pt) * 2004-04-14 2007-10-23 Wyeth Corp método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
RU2007127499A (ru) * 2005-02-15 2009-03-27 Вайет (Us) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
EA015922B1 (ru) 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
MX387669B (es) 2012-06-04 2025-03-18 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2017038925A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
RO120603B1 (ro) * 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
DK1658295T3 (da) * 2003-08-07 2007-09-24 Wyeth Corp Regioselektiv syntese af CCI-779
WO2005023254A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
RU2007127499A (ru) * 2005-02-15 2009-03-27 Вайет (Us) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме

Also Published As

Publication number Publication date
DE602004011398D1 (de) 2008-03-06
MXPA06007829A (es) 2006-09-01
DK1701698T3 (da) 2008-05-05
AR047180A1 (es) 2006-01-11
CR8491A (es) 2008-08-21
TW200526213A (en) 2005-08-16
ATE383859T1 (de) 2008-02-15
WO2005070393A3 (en) 2006-09-28
JP2007517879A (ja) 2007-07-05
ES2298861T3 (es) 2008-05-16
GT200500003A (es) 2005-08-18
PA8621201A1 (es) 2005-12-23
ZA200605631B (en) 2010-01-27
CA2552595A1 (en) 2005-08-04
IL176519A0 (en) 2006-10-05
CN1921861A (zh) 2007-02-28
DE602004011398T2 (de) 2009-01-15
RU2006122517A (ru) 2008-02-20
BRPI0418373A (pt) 2007-05-22
WO2005070393A2 (en) 2005-08-04
UA84903C2 (ru) 2008-12-10
PL1701698T3 (pl) 2008-03-31
US20050152983A1 (en) 2005-07-14
EP1701698A2 (en) 2006-09-20
PE20050683A1 (es) 2005-11-04
EP1701698B1 (en) 2008-01-16
AU2004314213A1 (en) 2005-08-04
CY1107373T1 (el) 2012-12-19
ECSP066757A (es) 2006-11-16
NO20062930L (no) 2006-10-02
PT1701698E (pt) 2008-03-27
KR20060130162A (ko) 2006-12-18
HK1090308A1 (en) 2006-12-22

Similar Documents

Publication Publication Date Title
HN2005000005A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779
CY1122161T1 (el) Συζευγμενα αντισωματα anti-cd38
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
EP1824442A4 (en) PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
SE0401342D0 (sv) Therapeutic compounds
EP4389752A4 (en) CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND THEIR USE
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2007063421A8 (en) Compositions and methods relating to treatment of cancer and infectious diseases
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
ATE434431T1 (de) Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
IS7383A (is) Skammtaform með stýrða lyflosun til inngjafar
MX2009013123A (es) Composiciones y metodos para modular la inflamacion usando fluoroquinolonas.
SV2006001989A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci - 779 ref. am-101453salvo
CA3297147A1 (en) Device and methods for administering a therapeutic composition to the pharyngeal muscle